Collectively, these findings suggest that ACT ameliorates MASLD, and this effect is associated with activation of PINK1/Parkin-related mitophagy markers, which improves mitochondrial quality control and ultimately reduces hepatic lipid deposition. The gene discussed is PRKN; the disease is metabolic dysfunction-associated steatotic liver disease.